Grant: Engage Grants Program
University of Saskatchewan
$25,000.00
Alpha-GPC and Plasmalogen Nootropics
FY 2017-18
Summary
Med-Life discoveries (MLD) has developed plasmalogen restoration as a therapy for Alzheimer's disease that is based on a synthetic plasmalogen precursor composed of naturally occurring metabolites. The drug is converted by the body into a variety of plasmalogen lipid species required by neurons. Preclinical evaluation of MLD's plasmalogen restoration therapy is nearly complete, and synthesis is being scaled up to support an FDA IND submission and a Phase I clinical trial. Together with our collaborators, MLD is in the final stages of planning for trials in patients with mild cognitive impairment. Patients treated with plasmalogen precursors are able to release acetyl choline to the synaptic cleft with greater efficiency. Similarly the compound glycerylphosphorylcholine (GPC) is sold as nootropic for treatment of Alzheimer's disease based on its action as a parasympathomimetic precursor of acetylcholine. GPC also acts as a nutraceutical and clinical studies show its effects on cognitive performance in Alzheimer's patients. GPC affects lipid metabolic rates as it is a precursor to phosphatidyl choline. It is low toxicity and it is consumed at high concentrations (300 mg to 1,200 mg daily) in most studies. An ethanol plant like the one in Belle Plaine, Saskatchewan could produce about 1 billion 500 mg doses per year. Individuals are self treating Alzheimer's with GPC and they might consume this compound in conjunction with other clinical treatments such as plasmalogens. It would be valuable to first determine the GPC quality. In the future, once a pure source of GPC is identified an appropriate clinical trial can be devised. Current commercial GPC preparations arise from lipid hydrolysis but GPC from ethanol production is new. Our goal in this proposal is to determine commercial GPC purity and compare it to GPC from ethanol production. We have prepared GPC concentrates in the laboratory and will scale up GPC production from ethanol. In future research we will determine if alpha-GPC is safe to use in conjunction with plasmalogen. NSERC ENGAGE proposal will conclude with the production of ~200 g of GPC at the University of Saskatchewan's Bioprocessing Pilot Plant.
Program
Engage Grants Program
Recipient
Location
Saskatchewan, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
522036-2017
Name nom
Reaney, Martin
Department département
Plant Sciences
Organization id
16
Institution établissement
University of Saskatchewan
Province en
Saskatchewan
Province fr
Saskatchewan
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
6103
Research subject group en
Food science and technology
Research subject group fr
Science et technologie de l'alimentation
Research subject en
Food processing, packaging, preservation and storage
Research subject fr
Transformation, conditionnement, conservation et stockage des aliments
Partie
1
Nb partie
1
Application title
Alpha-GPC and Plasmalogen Nootropics
Keyword
NSERC
Application summary
Med-Life discoveries (MLD) has developed plasmalogen restoration as a therapy for Alzheimer's disease that is based on a synthetic plasmalogen precursor composed of naturally occurring metabolites. The drug is converted by the body into a variety of plasmalogen lipid species required by neurons. Preclinical evaluation of MLD's plasmalogen restoration therapy is nearly complete, and synthesis is being scaled up to support an FDA IND submission and a Phase I clinical trial. Together with our collaborators, MLD is in the final stages of planning for trials in patients with mild cognitive impairment. Patients treated with plasmalogen precursors are able to release acetyl choline to the synaptic cleft with greater efficiency. Similarly the compound glycerylphosphorylcholine (GPC) is sold as nootropic for treatment of Alzheimer's disease based on its action as a parasympathomimetic precursor of acetylcholine. GPC also acts as a nutraceutical and clinical studies show its effects on cognitive performance in Alzheimer's patients. GPC affects lipid metabolic rates as it is a precursor to phosphatidyl choline. It is low toxicity and it is consumed at high concentrations (300 mg to 1,200 mg daily) in most studies. An ethanol plant like the one in Belle Plaine, Saskatchewan could produce about 1 billion 500 mg doses per year. Individuals are self treating Alzheimer's with GPC and they might consume this compound in conjunction with other clinical treatments such as plasmalogens. It would be valuable to first determine the GPC quality. In the future, once a pure source of GPC is identified an appropriate clinical trial can be devised. Current commercial GPC preparations arise from lipid hydrolysis but GPC from ethanol production is new. Our goal in this proposal is to determine commercial GPC purity and compare it to GPC from ethanol production. We have prepared GPC concentrates in the laboratory and will scale up GPC production from ethanol. In future research we will determine if alpha-GPC is safe to use in conjunction with plasmalogen. NSERC ENGAGE proposal will conclude with the production of ~200 g of GPC at the University of Saskatchewan's Bioprocessing Pilot Plant.